Список проголосовавших за комментарий " On The Wires<ul><li>Dunkin' Brands Group (<strong>DNKN</strong>) announced plans to remove artificial colors from its products in the U.S. As part of the company's ongoing efforts to offer guests great-tasting, high-quality products and cleaner menu labels, both the Dunkin' Donuts and Baskin-Robbins product development teams, in partnership with suppliers, have been working to eliminate synthetic colors from their food and beverages and replace the ingredients with naturally sourced colorings in the U.S. by the end of 2018.</li><li>BeiGene, Ltd. (<strong>BGNE</strong>) announced the dosing of the first patient in a pivotal clinical trial of BGB-3111, an investigational Bruton's Tyrosine Kinase (BTK) inhibitor, in Chinese patients with relapsed or refractory mantle cell lymphoma. BGB-3111 is also currently being evaluated in a global Phase III study in comparison with ibrutinib for the treatment of patients with Waldenström's Macroglobulinemia.</li><li>BeiGene, Ltd. (<strong>BGNE</strong>) announced that it will present data from the Phase IB dose expansion study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors in an oral presentation during a Clinical Trials Plenary Session at the 2017 American Association for Cancer Research (AACR) Annual Meeting. In addition, the company expects a decision in the first quarter of 2017 from its partner Merck KGaA on its continuation option to develop and commercialize BGB-283 outside China after Merck's review of Phase I data.</li><li>Citi Retail Services (<strong>C</strong>) announced it will renew its consumer financing agreement with Ford Motor Company (<strong>F</strong>).</li><li>Novan (<strong>NOVN</strong>) announced that data from the Company's Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV, will be presented during a Late-breaking Research forum at the 2017 Annual Meeting of the American Academy of Dermatology, or AAD, in Orlando, Florida.</li><li>Sigma Labs, Inc. (<strong>SGLB</strong>) announced that it has received a contract from Aerojet Rocketdyne, a subsidiary of Aerojet Rocketdyne Holdings (<strong>AJRD</strong>), as a follow-on to last year's award tied to a U.S. Air Force propulsion initiative. As previously announced in March, 2016, Sigma Labs' technology is being evaluated by Aerojet Rocketdyne for its contract with the Air Force for liquid-fueled rocket engine applications — part of a plan to transition away from the Russian-made RD-180 engines currently used on the Atlas V launch vehicle.</li><li>U.S. Department of Transportation Awards Booz Allen Hamilton (<strong>BAH</strong>) a Spot on $202 Million Contract to Support Work on Intelligent Transportation Systems</li></ul>"